The Long Run with Luke Timmerman

Ep123: Tariq Kassum on Single-Cell Analysis for Drug Discovery

Oct 27, 2022

01:15:26

Creator website

Highlights

AI Chapters

Episode notes

Single-Cell Genomics - What's It Going to Take?

01:41

How Did You Get Your First Job?

03:59

Pcsk9

03:05

Introduction

3min

The Long Run, Tarek Kasam

2min

I'm a Jan Exer. Fully Canadian.

2min

How Did You Land on Science?

3min

Doctor of Medicine - What Is It All About?

2min

What Kind of Doctor Did You Become While in Medical School?

2min

Medical School - How Did You Make the Move Out of Medicine?

3min

Can You Tell Me About Your Career in Healthcare?

4min

Do You Want to Be a Hedge Fund Analyst?

3min

10.

How Did You Get Your First Job?

4min

11.

The Quality Management Team at a Mid to Large Size Company

2min

12.

How Many Years Have You Been in Pharma Business Development?

3min

13.

Life Sciences Innovation in Calgary

2min

14.

TimmermanReport - Where Did You Go First?

4min

15.

How to Start a Biotech Company?

3min

16.

Bringing More Controllability to Cell Therapies

3min

17.

What I Learned About Celsius

3min

18.

Using Single Cell RNA Sequencing to Define Disease Phenotypes

2min

19.

Using Single Cell RNA Sequencing, You're Getting an Average Gene Expression

2min

20.

Using Bioinformatics in a Company?

2min

21.

The Core Vision of Celsius

2min

22.

How Do You Get Human Tissue Samples?

2min

23.

Single-Cell RNA Sequencing - What's the Promise?

3min

24.

Drug Discovery for Inflammatory Bowel Disease

2min

25.

Are You Thinking of a Combination Therapy?

2min

26.

Collaboration With Servier on CRC

2min

27.

Single-Cell Genomics - What's It Going to Take?

2min

28.

Data Hygiene and Data Interconnectivity

2min

29.

The Future Is Going to Be to Start With the Humans

2min

30.

Pcsk9

3min

Tariq Kassum, CEO of Cambridge, Mass.-based Celsius Therapeutics, on using single cell technology for drug discovery.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.